The most direct challenge to the integrity of science appears in “Authorship-for-Sale: From Fake Papers to Forensic Scientometrics,” by JMIR Correspondent Cliff Dominy. The article investigates the expansion of paper mills, commercial operations that produce fabricated or manipulated manuscripts and sell authorship positions to researchers seeking publications. These businesses can generate entire false studies, invent data, imitate academic language, and place paying customers among the listed authors. Artificial intelligence is accelerating the process by making it easier to produce plausible text, synthetic images, fabricated references, and statistical patterns that may escape superficial review. The result is not merely a problem of plagiarism or poor scholarship. It is a contamination of the scientific record that can distort evidence, waste research funding, and undermine confidence in legitimate discoveries.

Dominy speaks with research integrity expert Leslie McIntosh and meta-scientist Reese Richardson about methods that could expose fraudulent papers and false authorship. Bibliometric analysis, for example, can examine unusual publication patterns, repeated collaborations, improbable citation networks, sudden changes in writing style, or clusters of papers linked to suspicious organizations. Identity verification may help determine whether a listed researcher actually contributed to a study and whether institutional affiliations are genuine. Forensic scientometrics combines these signals with analyses of language, references, peer-review histories, and research outputs. Yet detection alone may not solve the problem. The incentives behind paper mills are rooted in academic systems that reward publication volume, career advancement, and institutional prestige. Without reforming those pressures, investigators may continue fighting symptoms while the market for fraudulent authorship expands.

A different form of algorithmic intervention is being tested in the home. In “Can Intelligent Monitoring Help Older Adults Live Safely at Home Longer?”, JMIR Correspondent Jenna Congdon reports on the Comprehensive Healthcare at Home initiative, a partnership between CHAH Technology and McMaster University’s Institute for Research on Aging. The system is designed to support older adults who wish to live independently while reducing the risks associated with falls, illness, and delayed emergency response. Rather than relying exclusively on wearable devices or manual check-ins, ambient monitoring uses sensors placed within the living environment to observe patterns such as movement, activity, room occupancy, and potentially changes in daily routines. Algorithms then interpret these streams of data to identify deviations that may signal an accident or emerging health problem.

The technical challenge is distinguishing meaningful clinical changes from ordinary variation. An older adult may sleep longer, skip a meal, or move less on a particular day without being in danger. A useful monitoring system therefore needs models capable of learning an individual’s baseline behavior and estimating when a deviation is sufficiently unusual to justify an alert. Such systems could combine time-series analysis, anomaly detection, and risk prediction, while sending information to caregivers or health professionals rather than making autonomous medical decisions. Congdon emphasizes that the promise of intelligent monitoring is inseparable from questions about cost, privacy, consent, and control. Continuous observation can become intrusive if residents do not understand what is collected, how long it is stored, or who can access it. The technology will be trusted only if older adults remain active participants in its use.

The impact of digital systems on health-care workers is explored in “US Nursing Strikes Highlight Systemic Challenges: Can Digital Health Be Part of the Solution?”, by JMIR Correspondent and researcher Benedette Cuffari. The article connects recent nursing labor disputes with a broader debate over whether technology can relieve staff shortages and improve working conditions. Automated scheduling platforms may help match staffing levels with patient demand, while reducing the administrative burden associated with shift planning. Ambient artificial-intelligence scribes can listen during clinical encounters, identify relevant information, and generate draft documentation for review. Virtual simulation platforms can also allow nursing students and practicing clinicians to rehearse complex scenarios without placing patients at risk.

These tools, however, are not automatically beneficial. Poorly designed scheduling systems can make staffing decisions less transparent and leave nurses with less control over their working lives. AI-generated clinical notes may save time but can introduce omissions, incorrect interpretations, or additional verification work. Simulation platforms may expand access to training, yet they cannot reproduce every social, emotional, and physical dimension of patient care. Cuffari reports comments from Joe-Ann Fergus, Director of Industrial Relations at the Massachusetts Nurses Association, stressing that nurses must participate in the design and evaluation of digital systems. Their practical knowledge is essential for identifying hidden burdens, unsafe workflows, and technical solutions that appear efficient on paper but fail at the bedside. Technology that is imposed without consultation may deepen workplace strain instead of reducing it.

In China, artificial intelligence is beginning to alter not only clinical workflows but also the relationship between patients and physicians. In “When the Algorithm Starts Seeing the Patient First: China and the Changing Role of Physicians,” physician and health strategist Ruby Wang examines how established digital-health infrastructure has enabled the country to integrate AI into patient-facing services. Online consultations, electronic records, mobile health platforms, and automated triage systems have created channels through which patients can interact with health services before seeing a doctor. AI can process symptoms, prioritize cases, identify possible diagnoses, and recommend clinical pathways at a scale that would be difficult for individual physicians to match. In principle, this expands clinical capacity and allows medical professionals to focus on cases requiring judgment, communication, and complex intervention.

The redistribution of work also redistributes authority. When an algorithm evaluates a patient before a physician does, its output may influence which symptoms receive attention, how urgently a patient is seen, and which treatments are considered. Machine-learning systems typically identify statistical associations from large datasets rather than reasoning about disease in the same way clinicians do. Their performance can deteriorate when patients differ from the populations represented in training data, and their recommendations may be difficult to explain even when they are accurate. Wang warns that AI could create new obligations for physicians, who may be expected to verify automated decisions while remaining responsible for outcomes they did not initiate. Patients with limited digital literacy may also face new barriers if access to care increasingly depends on navigating apps, automated interfaces, or online registration systems.

The fifth article turns to a major diagnostic challenge in Africa, where digital tools alone cannot overcome gaps in laboratory capacity, connectivity, and geographic access. In “To Bridge the Hepatitis B Diagnosis Gap in Africa, Innovation Must Go Beyond Digital,” science journalist and JMIR Correspondent Sharon Muzaki reports on the work of South African virologist Dr. Nondumiso Nkosi. Hepatitis B is caused by a virus that can persist in the liver and lead over time to cirrhosis, liver failure, or hepatocellular carcinoma. Diagnosis commonly relies on detecting viral antigens, antibodies, or viral DNA in blood. Yet conventional testing may miss occult hepatitis B infection, a condition in which viral genetic material remains detectable even though the surface antigen normally used as a marker is absent or below the test’s detection threshold.

Nkosi’s team is developing HepaSure as a complementary point-of-care tool rather than a replacement for laboratory or digital diagnostics. The prototype is intended to identify infections that conventional screening could overlook and to bring testing closer to patients in settings without advanced laboratory infrastructure. Technically, a point-of-care assay must balance analytical sensitivity with simplicity, speed, stability, and affordability. It must function with limited equipment, tolerate transport and storage conditions that may be difficult to control, and produce results that health workers can interpret reliably. Digital platforms may help record results, track patients, or connect local services with specialists, but they cannot compensate for the absence of a physical test or trained personnel. HepaSure reflects a broader principle in global health innovation: the most useful technology is not always the most sophisticated one, but the one that works reliably within the realities of the communities it is meant to serve.

Across the five features, AI and digital health emerge neither as inevitable solutions nor as simple threats. Algorithms can detect patterns across enormous datasets, automate repetitive tasks, monitor vulnerable people, and extend scarce expertise. At the same time, they can encode bias, increase surveillance, shift responsibility without increasing authority, and exclude people who lack money, connectivity, technical confidence, or the ability to give meaningful consent. The articles argue that effective innovation requires technical validation as well as institutional accountability. Systems must be evaluated in real clinical environments, their errors must be measured, and the people affected by them must have a voice in their design. Whether addressing fraudulent research, aging at home, nursing workloads, clinical decision-making, or hepatitis B, the decisive question is not whether technology is advanced. It is whether it strengthens trustworthy human systems rather than quietly replacing them.

Subject of Research: People

Article Title: JMIR Publications Releases Five Feature Articles on Digital Scholarship and Clinical Practice

News Publication Date: August 24, 2026

Web References: https://www.jmir.org/2026/1/e109033; https://www.jmir.org/2026/1/e109278; https://www.jmir.org/2026/1/e109376; https://www.jmir.org/2026/1/e108939; https://www.jmir.org/2026/1/e109287

References: Dominy C. “Authorship-for-Sale: From Fake Papers to Forensic Scientometrics.” Journal of Medical Internet Research. 2026;28:e109033. DOI: 10.2196/109033. Congdon J. “Can Intelligent Monitoring Help Older Adults Live Safely at Home Longer?” Journal of Medical Internet Research. 2026;28:e109278. DOI: 10.2196/109278. Cuffari B. “US Nursing Strikes Highlight Systemic Challenges: Can Digital Health Be Part of the Solution?” Journal of Medical Internet Research. 2026;28:e109376. DOI: 10.2196/109376. Wang R. “When the Algorithm Starts Seeing the Patient First: China and the Changing Role of Physicians.” Journal of Medical Internet Research. 2026;28:e108939. DOI: 10.2196/108939. Muzaki S. “To Bridge the Hepatitis B Diagnosis Gap in Africa, Innovation Must Go Beyond Digital.” Journal of Medical Internet Research. 2026;28:e109287. DOI: 10.2196/109287.

Keywords: artificial intelligence; digital health; health care; clinical medicine; academic publishing; research integrity; paper mills; nursing; patient monitoring; aging at home; China; hepatitis B; point-of-care diagnostics; global health; medical ethics

The concept builds on the increasingly influential idea of “Medicine 3.0,” which emphasizes disease prevention, personalized care, early risk detection, and the extension of healthspan—the period of life spent in good health. Medicine 4.0 retains those goals but adds a third dimension to the traditional focus on lifespan and healthspan: access. In Macdonald’s framework, a healthcare system cannot be considered fully advanced if its most effective interventions are available only to people with the financial, geographic, or social resources to obtain them.

The proposed model treats access as more than the ability to visit a doctor or purchase a medicine. It includes access to preventive screening, essential treatments, reliable health information, clinical trials, and the infrastructure required to deliver care. It also includes access to scientific inquiry itself. According to the commentary, potentially important research questions can be delayed or neglected when regulatory systems, funding priorities, political pressures, cultural assumptions, or commercial interests determine which areas of science are considered acceptable or profitable.

This distinction is technically important because modern healthcare increasingly depends on prevention rather than treatment after disease has developed. Vaccination, blood-pressure control, cancer screening, lipid reduction, nutritional interventions, and early detection can reduce disease risk long before symptoms appear. Yet the effectiveness of these measures at the population level depends on coverage. A highly effective intervention can have limited public-health impact if it reaches only a small, affluent segment of society. In epidemiological terms, the benefit of an intervention is shaped not only by its individual efficacy but also by its distribution across the population.

The commentary points to persistent differences in access between and within countries. In wealthier nations, advanced preventive medicine may be linked to private healthcare, specialist services, expensive insurance plans, or subscription-based programs. In lower-income regions, barriers may involve shortages of essential medicines, inadequate primary-care facilities, limited vaccination infrastructure, unreliable transport, and a lack of clean water. These conditions can prevent communities from benefiting from advances that are already scientifically established, making innovation alone insufficient to improve global health.

Macdonald also argues that scientific research requires a form of access that is often overlooked. The paper discusses the history of psychedelic research as an example of how external forces can shape the scientific agenda. For decades, regulatory restrictions, political responses, and cultural stigma limited clinical investigation of psychedelic compounds. Renewed research has since examined their possible use in conditions including post-traumatic stress disorder, depression, alcohol use disorder, and anxiety associated with terminal illness. The example does not establish that these treatments are universally safe or effective; rather, it illustrates the importance of allowing carefully controlled studies to test controversial hypotheses.

In clinical science, such openness must be balanced by rigorous safeguards. New interventions require laboratory research, dose-finding studies, randomized clinical trials, long-term monitoring, and evaluation of adverse effects before they can be incorporated into routine care. Macdonald’s argument is not that every unconventional idea should be adopted, but that scientific questions should be assessed through evidence rather than rejected solely because they conflict with prevailing political, cultural, or commercial expectations. Removing unnecessary barriers to investigation can increase the chance that useful therapies are identified, while scientific standards determine whether those therapies should be used.

The paper further examines the role of financial incentives in shaping healthcare priorities. Healthcare systems often reward activities that generate immediate revenue, such as procedures, consultations, and long-term treatment, while providing weaker incentives for prevention or interventions whose benefits may appear years later. This creates a structural problem: the economic value of preventing a disease may be distributed across society and realized in the future, whereas the costs of prevention are frequently immediate and concentrated. Medicine 4.0 therefore calls for payment and policy systems that reward measurable improvements in population health, rather than focusing primarily on the volume of services delivered.

Digital health and artificial intelligence could either strengthen or undermine this goal. Smartphone applications, wearable sensors, remote monitoring, automated risk assessment, and machine-learning systems can make some forms of preventive care more scalable. Algorithms can identify patterns in physiological data, support earlier warnings, and help clinicians manage large populations. However, these technologies require access to devices, internet connectivity, technical support, and trustworthy data governance. If health platforms depend on costly subscriptions, paywalls, or advertising models that exploit personal information, they could deepen existing inequalities instead of democratizing care.

The Medicine 4.0 framework ultimately presents access as a scientific and ethical requirement rather than an optional social benefit. Inspired in part by Francis Bacon’s view of science as a means of improving the human condition, the commentary argues that medical progress should be judged by both the sophistication of new discoveries and the breadth of their reach. A healthcare system that combines prevention, personalized risk management, open inquiry, and equitable distribution, Macdonald suggests, would be better positioned to convert scientific progress into longer and healthier lives for the whole population.

Subject of Research: People

Article Title: “Medicine 4.0: the era of revolutionary access”

Web References: https://doi.org/10.3389/fmed.2026.1903811

Keywords

Medicine 4.0, healthcare access, preventive medicine, healthspan, personalized medicine, public health, medical research, scientific inquiry, digital health, artificial intelligence, health inequality, healthcare policy

Dr. Nadkarni’s appointment is a culmination of a series of progressive initiatives undertaken by Mount Sinai to implement artificial intelligence within healthcare. With the recent unveiling of a state-of-the-art AI facility, the institution aims to propel innovation and collaborative research in translational medicine. This facility will serve as a hub for cutting-edge projects that integrate AI technology into various aspects of patient care, education, and research.

AI’s integration into medicine is not merely about adopting new technology; it requires a cultural shift within healthcare systems to prioritize data-driven decision-making. Dr. Nadkarni’s goal is to ensure that AI methodologies are adopted in a way that not only improves clinical outcomes but also addresses concerns about bias in technology, their transparency, and ethical considerations. By working closely with existing clinicians and researchers across all departments at Mount Sinai, he will spearhead efforts aimed at developing AI tools that are effective, equitable, and beneficial for all patients.

One of the significant advancements on the horizon involves a new AI tool specifically designed for students at the Icahn School of Medicine. This initiative is expected to revolutionize medical education by integrating advanced AI resources directly into the curriculum, thus equipping the next generation of healthcare professionals with the skills necessary to leverage AI technologies in their practice. Additionally, this integration will provide students with hands-on experience in using AI for research and patient care, serving as a critical aspect of modern medical training.

Beyond education, Mount Sinai has also made substantial investments in enhancing its computational and data ecosystems. This includes the establishment of the largest supercomputing cluster at any academic medical center globally. This computational power is vital for conducting large-scale analyses and developing sophisticated AI algorithms that can lead to new insights and better patient management practices.

Dr. Nadkarni’s leadership is underscored by a strong collaborative ethos. He will work closely with Lisa S. Stump, the Chief Digital Information Officer and Dean for Information Technology at the Icahn School of Medicine. This partnership aims to unite data and technological platforms across the Mount Sinai Health System, focusing on facilitating quicker cures for diseases, enhancing patient outcomes, and streamlining operational efficiency. Their collaborative efforts signify a holistic approach to integrating AI effectively within the healthcare framework.

Mount Sinai’s commitment to AI extends beyond mere research; it signifies a paradigm shift in how healthcare is delivered. The institution fosters a culture that emphasizes safe and equitable AI adoption, positioning itself as a model for progressive and AI-enabled learning health systems. This ethos is echoed in statements from institutional leaders who express their enthusiasm for Dr. Nadkarni’s vision and the transformative potential of AI within clinical contexts.

As an advocate for responsible AI implementation, Dr. Nadkarni emphasizes the importance of conducting research that is not only innovative but also free from inherent biases. His extensive background in AI applications in healthcare includes pioneering work that addresses bias in algorithmic designs and ensures that AI tools are developed with equity in mind. This focus is crucial in a field where the implications of biased data can significantly affect patient care and health outcomes.

Dr. Nadkarni’s remarkable portfolio includes numerous patents for AI applications in medicine, showcasing his active role in bridging the gap between AI and clinical practice. He is notably recognized for co-inventing the first FDA-approved AI bioprognostic tool for assessing kidney disease, a milestone achievement that underscores the practical impact AI can have on improving diagnostic accuracy and patient stratification.

Moreover, being the Co-Director of The Charles Bronfman Institute for Personalized Medicine and Chief of the Division of Data-Driven and Digital Medicine at Mount Sinai, Dr. Nadkarni’s focus lies in integrating AI methodologies into precise patient care frameworks. His research encompasses various critical areas, including the implementation of predictive AI technologies across diverse medical conditions, highlighting the transformative potential of AI in improving clinical outcomes.

Given Dr. Nadkarni’s extensive contributions to national and international discussions on leveraging AI in healthcare, his appointment marks a pivotal moment for Mount Sinai. The institution is poised to lead the next wave of AI integration into medicine, firmly situating itself as a key player in global health innovation. Dr. Nadkarni’s innovative mindset and collaborative spirit are expected to drive vital advancements in healthcare delivery and scientific inquiry.

Recognizing the urgency of adopting AI responsibly, Dr. Nadkarni’s overarching vision is to ensure that the AI solutions developed are aligned with ethical standards and aimed at enhancing patient care while mitigating potential risks. His leadership embodies a comprehensive approach to technology integration that prioritizes patient welfare and systemic improvement, resonating deeply within the healthcare community.

As Mount Sinai continues to unfold its ambitious AI endeavors, the broader implications of Dr. Nadkarni’s appointment underscore a transformative journey that extends well beyond the institution itself. By setting new benchmarks for the integration of artificial intelligence in healthcare, Mount Sinai aims to amplify the collective impact of scientific advancements on global health outcomes.

Subject of Research: Artificial Intelligence in Healthcare
Article Title: Girish N. Nadkarni Appointed as Chair of Windreich Department of Artificial Intelligence and Human Health, Pioneering AI in Medicine
News Publication Date: January 30, 2025
Web References: Mount Sinai’s AI Department
References: Mount Sinai Health System
Image Credits: Credit: Mount Sinai Health System

Keywords: Artificial Intelligence, Healthcare Innovation, Biomedical Engineering, Clinical Applications of AI, Medical Education, Health Outcomes, Data-Driven Medicine, Ethical AI Implementation, AI and Bias in Healthcare.